Status: Not yet recruiting
Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous Familial Hypercholesterolemia
This trial is a multicenter, open-label, phase II clinical study, aiming to evaluate the efficacy and safety of SYH2070 injection in participants with HoFH.
Participants needed: 18
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Updated: May 15, 2026
Eligibility criteria
Age ≥18 years old, male or female, and weight ≥40 kg. [+6]
The genetic diagnosis was for heterozygous familial hypercholesterolemia; [+17]